Kynos Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 9

Employees

  • Latest Deal Type
  • M&A

Kynos Therapeutics General Information

Description

Operator of a Biotech company intended to fulfill the unmet medical need for new therapies. The company's therapy offers to block the action of Kaiser-Meyer-Olkin (KMO) which is a key enzyme at the interface of inflammation, immunity, and metabolism and regulation of systemic inflammation and the pathology of conditions where there is a pressing need for new medicines, providing the clinical industry with a new generation of potent inhibitors.

Contact Information

Website
www.kynostx.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 1-3 Charter Square
  • Sheffield S1 4HS
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Corporate Office
  • 1-3 Charter Square
  • Sheffield S1 4HS
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kynos Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 29-Oct-2024 Completed Pre-Clinical Trials
4. Early Stage VC (Series A) 07-Apr-2022 Completed Pre-Clinical Trials
3. Grant 01-Mar-2022 Completed Pre-Clinical Trials
2. Accelerator/Incubator 01-Jan-2022 Completed Pre-Clinical Trials
1. University Spin-Out Completed Startup
To view Kynos Therapeutics’s complete valuation and funding history, request access »

Kynos Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Series A
To view Kynos Therapeutics’s complete cap table history, request access »

Kynos Therapeutics Patents

Kynos Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10246447-B2 3-(6-chloro-3-oxo-3,4-dihydro-(2h)-1,4-benzoxazin-4-yl) propanoic acid derivatives and their use as kmo inhibitors Active 22-May-2015
US-20180170920-A1 3-(6-chloro-3-oxo-3,4-dihydro-(2h)-1,4-benzoxazin-4-yl) propanoic acid derivatives and their use as kmo inhibitors Active 22-May-2015
US-10611756-B2 Method of treating pancreatitis using 1,4-benzoxazine derivatives Active 22-May-2015
US-20190169178-A1 Methods Active 22-May-2015
US-10273232-B2 3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)propanoic acid useful as kynurenine monooxygenase inhibitors Active 19-Dec-2014 A61K31/423
To view Kynos Therapeutics’s complete patent history, request access »

Kynos Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kynos Therapeutics Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Creative Destruction Lab Accelerator/Incubator
Epidarex Capital Venture Capital Minority
Gershon Capital Venture Capital Minority
IP Group Venture Capital Minority
Innovate UK Government
You’re viewing 5 of 8 investors. Get the full list »

Kynos Therapeutics FAQs

  • When was Kynos Therapeutics founded?

    Kynos Therapeutics was founded in 2020.

  • Where is Kynos Therapeutics headquartered?

    Kynos Therapeutics is headquartered in Sheffield, United Kingdom.

  • What is the size of Kynos Therapeutics?

    Kynos Therapeutics has 9 total employees.

  • What industry is Kynos Therapeutics in?

    Kynos Therapeutics’s primary industry is Drug Discovery.

  • Is Kynos Therapeutics a private or public company?

    Kynos Therapeutics is a Private company.

  • What is Kynos Therapeutics’s current revenue?

    The current revenue for Kynos Therapeutics is .

  • How much funding has Kynos Therapeutics raised over time?

    Kynos Therapeutics has raised $8.53M.

  • Who are Kynos Therapeutics’s investors?

    Creative Destruction Lab, Epidarex Capital, Gershon Capital, IP Group, and Innovate UK are 5 of 8 investors who have invested in Kynos Therapeutics.

  • When was Kynos Therapeutics acquired?

    Kynos Therapeutics was acquired on 29-Oct-2024.

  • Who acquired Kynos Therapeutics?

    Kynos Therapeutics was acquired by Dr Falk Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process